Brain and Acute Leukemia, Cytoplasmic Proteins (BAALC)

Human Brain and Acute Leukemia, Cytoplasmic (BAALC) interaction partners

1. BAALC expression-based minimal residual disease detection during therapy may be considered a strategy to identify patients at high risk of relapse.

2. Study provide evidence for an association of rs62527607 [GT] SNP of BAALC gene with multidrug resistance in childhood ALL.

3. BAALC and ERG (show ERG Proteins) genes are specific significant molecular markers in acute myeloid leukemia (show BCL11A Proteins) disease progression, response to treatment and survival.

4. demonstrated that BAALC blocks ERK (show EPHB2 Proteins)-mediated monocytic differentiation of acute myeloid leukemia (show BCL11A Proteins) cells by trapping Kruppel-like factor 4 (KLF4 (show KLF4 Proteins)) in the cytoplasm and inhibiting its function in the nucleus

5. combined determination of both miR (show MLXIP Proteins)-3151 and BAALC improved this prognostic stratification, with patients with low levels of both parameters showing a better outcome compared with those patients harboring increased levels of one or both markers

6. study indicates that overexpression of BAALC serves as an independent prognostic biomarker in acute myeloid leukemia (show BCL11A Proteins)

7. Evaluating WT1 (show WT1 Proteins) and BAALC gene expression at diagnosis may improve standard risk stratification and possibly refine the therapeutic approach for Myelodysplastic Syndromes patients.

8. Thus low MDR1/low BAALC expression identifies a subgroup of intermediate cytogenetic risk AML (show RUNX1 Proteins) patients with a remarkably good long-term outcome achieved by chemotherapy alone.

9. miR (show MLXIP Proteins)-3151 introns within BAALC have roles in driving leukemogenesis by deregulating the TP53 (show TP53 Proteins) pathway

10. Higher BAALC expression and FLT3 (show FLT3 Proteins)-ITD mutation, both individually and in combination, were associated with worse survival outcomes in CN-AML (show RUNX1 Proteins), and this was also applicable in NPM1 (show NPM1 Proteins)-mutated CN-AML (show RUNX1 Proteins), known as a favorable-risk group.

Mouse (Murine) Brain and Acute Leukemia, Cytoplasmic (BAALC) interaction partners

1. BAALC/Baalc is a marker of the mesodermal lineage, especially muscle.